DEEPULL
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functional status on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
DEEPULL
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Total Employee:
1+
Status:
Active
Total Funding:
3.5 M EUR
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Employees Featured
Founder
Investors List
Alta Life Sciences
Alta Life Sciences investment in Series A - DeepUll
Kurma Partners
Kurma Partners investment in Series A - DeepUll